Business Context and Reporting Period
Company: Henry Schein, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 5, 2004
Event: Issuance of a press release revising 2004 earnings per diluted share guidance.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on the revision of earnings guidance rather than reporting period-end financial results.
Material Changes
The primary material change is the downward revision of the company's 2004 earnings per diluted share guidance. This adjustment was necessitated by an external event: Chiron Corporation announced it would not supply Fluvirin influenza vaccine for the current influenza season.
Guidance, Outlook, and Risks
- Guidance Revision: Management has revised its 2004 earnings per diluted share outlook.
- Cause: The revision is a direct result of the supply disruption of the Fluvirin influenza vaccine by Chiron Corporation.
- Risk/Contingency: The filing highlights the risk of supply chain dependency on third-party manufacturers for key products like influenza vaccines.
Investor Verification Checklist
- Verify the specific numerical range of the revised 2004 earnings per diluted share guidance in the attached press release (Exhibit 99.1).
- Confirm the extent of Henry Schein's revenue exposure to the Fluvirin influenza vaccine.
- Assess the potential impact of the Chiron supply decision on the company's overall 2004 operating margins.